

IN THE CLAIMS:


This listing of claims will replace all prior versions and listing of claims in the application.

Please amend claims 1, 3, 4, 7-10 and 13-16 as indicated.

Please cancel claims 2, 5, 6, 11, 12 and 17-20 without prejudice or disclaimer of the subject matter therein.

Listing of claims:

Claim 1 (currently amended): A compound of formula (I):



(I)

wherein:

~~R¹ is halo, cyano, C₁₋₃alkyl or C₁₋₃alkoxy;~~

~~p is 0-2; wherein the values of R¹ may be the same or different;~~

~~R² is amino, R⁶ or R⁶-NH-R⁶-NH₂;~~

~~R³ is hydrogen, halo or cyano;~~

~~R⁴ is C₃₋₆cycloalkyl, C₃₋₆cycloalkylC₁₋₄alkyl, benzyl, or heterocyclyl;~~

~~heterocyclylC₁₋₄alkyl or 1-methoxyprop-2-yl; wherein R⁴ may be optionally substituted on ring carbon by one or more methyl, ethyl, methoxy, ethoxy, propoxy, trifluoromethyl, trifluoromethoxy, 2,2,2-trifluoroethoxy or cyclopropylmethoxy; and wherein if said heterocyclyl contains an NH moiety that nitrogen may be optionally substituted by one or more methyl, ethyl, acetyl, 2,2,2-trifluoroethyl or methoxyethyl;~~

R^5 is C_{1-6} alkyl or C_{2-6} alkenyl; wherein R^5 may be optionally substituted on carbon by one or more methoxy, ~~ethoxy, propoxy, trifluoromethyl, trifluoromethoxy, 2,2,2-trifluoroethoxy or cyclopropylmethoxy;~~

R^6 is C_{1-4} alkyl, C_{2-4} alkenyl, ~~C_{2-4} alkynyl,~~ C_{3-6} cycloalkyl, C_{3-6} cycloalkyl C_{1-3} alkyl, a ~~heterocyclic group or~~ (heterocyclic group) C_{1-3} alkyl; wherein R^6 may be optionally substituted on carbon by one or more ~~methyl, ethyl, methoxy, ethoxy, propoxy, or trifluoromethyl, trifluoromethoxy, 2,2,2-trifluoroethoxy or cyclopropylmethoxy;~~ and wherein if said heterocyclic group contains an ~~NH~~ moiety that nitrogen may be optionally substituted by one or more ~~methyl, ethyl, acetyl, 2,2,2-trifluoroethyl or methoxyethyl;~~

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 2 (cancelled).

Claim 3 (currently amended): The A-compound of formula (I) according to claim 1 ~~any one of claims 1-2~~ wherein R^2 is $R^6-NH-R^6-NH_2$ wherein R^6 is C_{1-4} alkyl, C_{2-4} alkenyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkyl C_{1-3} alkyl or (heterocyclic group) C_{1-3} alkyl; and wherein R^6 may be optionally substituted on carbon by one methoxy, ethoxy or trifluoromethyl; or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 4 (currently amended): The A-compound of formula (I) according to claim 1 ~~any one of claims 1-3~~ wherein R^3 is hydrogen; or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 5 (cancelled).

Claim 6 (cancelled).

Claim 7 (**currently amended**): The A-compound of formula (I) as claimed in claim 1 (as depicted in claim 1) wherein:

p is 0;

R² is methylamino, allylamino, *t*-butylamino, 2-methoxyethylamino, 2-ethoxyethylamino, 3-methoxypropylamino, cyclopropylamino, cyclobutylamino, cyclopropylmethylamino, 2,2,2-trifluoroethylamino, tetrahydrofur-2-ylmethylamino or pyrid-2-ylmethylamino;

R³ is hydrogen;

R⁴ is cyclopropylmethyl, 2-cyclopropylethyl, cyclobutyl, cyclopropyl, cyclopentyl, benzyl, 1-methoxyprop-2-yl or tetrahydrofur-3-yl;

R⁵ is methyl, ethyl, propyl, methoxymethyl or 2-methylprop-1-enyl;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 8 (**currently amended**): The A-compound of formula (I) as claimed in claim 1 (as depicted in claim 1) selected from:

4-(1-cyclopentyl-2-methylimidazol-5-yl)-2-{4-[*N*-(cyclopropyl)sulphamoyl]anilino} pyrimidine;

4-(1-methoxyprop-2-yl-2-methylimidazol-5-yl)-2-{4-[*N*-(tetrahydrofur-2-ylmethyl)sulphamoyl]anilino}pyrimidine;

4-(1-cyclopropylmethyl-2-methylimidazol-5-yl)-2-{4-[*N*-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine;

4-(1-cyclopropylmethyl-2-methylimidazol-5-yl)-2-{4-[*N*-(2,2,2-trifluoroethyl)sulphamoyl]anilino}pyrimidine;

4-(1-cyclopropylmethyl-2-methylimidazol-5-yl)-2-{4-[*N*-(cyclobutyl)sulphamoyl]anilino}pyrimidine;

4-(1-cyclopropylethyl-2-methylimidazol-5-yl)-2-{4-[*N*-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine;

4-(1-cyclopropylethyl-2-methylimidazol-5-yl)-2-{4-[*N*-(tetrahydrofur-2-ylmethyl)sulphamoyl]anilino}pyrimidine;

4-(1-cyclopropylethyl-2-methoxymethylimidazol-5-yl)-2-{4-[N-(2-ethoxyethyl)sulphamoyl]

anilino}pyrimidine; and

~~4-(1-methoxyprop-2-yl-2-propylimidazol-5-yl)-2-{4-[N-(2-methoxyethyl)~~

~~sulphamoyl]anilino}pyrimidine; and~~


4-(1-cyclopropylmethyl-2-ethylimidazol-5-yl)-2-{4-[N-(2-methoxyethyl)

sulphamoyl]anilino}pyrimidine;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.


Claim 9 (**currently amended**): A process for preparing a compound of formula (I) as claimed in claim 1 or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof which process (wherein R^1 , R^2 , R^3 , R^4 , R^5 and p are, unless otherwise specified, as defined in claim 1) comprises of:

Process a) reaction of a pyrimidine of formula (II):



(II)


wherein L is a displaceable group; with an aniline of formula (III):



(III)


or

Process b) reacting a compound of formula (IV):



(IV)

with a compound of formula (V):




(V)

wherein T is O or S; Rˣ may be the same or different and is C₁₋₆alkyl;


Process c) for compounds of formula (I) where R² is amino or a group $\underline{R^6-NH-R^6-NH_2}$;

reacting a pyrimidine of formula (VI):



(VI)


wherein X is a displaceable group; with an amine of formula (VII):



(VII)


wherein R^a is hydrogen or R⁶;

Process d) reacting a pyrimidine of formula (VIII)



(VIII)


with a compound of formula (IX):



(IX)

where Y is a displaceable group; or

Process e) for compounds of formula (I) wherein R² is R⁶; oxidising a compound of formula (X):



(X)

and thereafter optionally if necessary:

- i) converting a compound of the formula (I) into another compound of the formula (I);
- ii) removing any protecting groups;
- iii) forming a pharmaceutically acceptable salt or *in vivo* hydrolysable ester.

Claim 10 (**currently amended**): A pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, according to any one of claims 1, 2-4 and 7-8-1-8, in association with a pharmaceutically-acceptable diluent or carrier.

Claims 11-12 (**cancelled**).

Claim 13 (**currently amended**): ~~The use of a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, according to any one of claims 1-8, in the manufacture of a medicament for use in~~ A method for the production of a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal such as man, which method comprises administering to said animal an effective amount of a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, according to any one of claims 1, 3-4 and 7-8.

Claim 14 (**currently amended**): ~~The use of a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, according to any one of claims 1-8, in the manufacture of a medicament for use in~~ A method for the treatment of solid tumour cancers (solid tumours and leukaemias), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation, which method comprises administering to said animal an effective amount of a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, according to any one of claims 1, 3-4 and 7-8.

Claim 15 (**currently amended**): ~~The use~~ A method for the treatment of cancer in a warm-blooded animal, which method comprises administering to said animal an effective

amount of a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, according to any one of claims 1, 3-4 and 7-8-1-8, ~~in the manufacture of a medicament for use in the treatment of cancer.~~

Claim 16 (**currently amended**): The method-use according to claim 15 wherein the cancer is selected from leukaemia, breast cancer, lung cancer, colorectal cancer, stomach cancer, prostate cancer, bladder cancer, pancreatic cancer, ovarian cancer, liver cancer, kidney cancer, skin cancer and cancer of the vulva.

Claims 17-20 (**cancelled**).